Advertisement

Topics

GSK’s shingles vaccine Shingrix succeeds in phase 3 revaccination trial

05:35 EDT 22 Jun 2017 | Pharmaceutical Business Review

GSK’s shingles vaccine candidate Shingrix (HZ/su) met its primary objective of inducing a strong immune response in older patients in a phase 3 revaccination trial.

Original Article: GSK’s shingles vaccine Shingrix succeeds in phase 3 revaccination trial

NEXT ARTICLE

More From BioPortfolio on "GSK’s shingles vaccine Shingrix succeeds in phase 3 revaccination trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...